Nov 16, 2009 | Bizjournals
Drug firm Metabolex raises a new $8.6M
In a tough capital environment, especially for drug companies focusing on diabetes treatments, Metabolex Inc.
Metabolex, Inc. Closes $8.6 Million Financing Round
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, today announced it had closed an additional $8.6 million in financing.
Metabolex Announces Positive Phase 1 Clinical Trial Results of MBX-2982
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from two multiple ascending dose Phase 1 clinical trials of MBX-2982. MBX-2982 is a potent, selective, orally active agonist of G protein-coupled receptor 119 , a ...
Also on Topix